BAAR, Switzerland - (NewMediaWire) - August 8, 2024 - PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today ...

Proceeds from the Series D financing will be used to advance and accelerate FogPharma’s growing pipeline of hyperstabilized α-helical (Helicon™) polypeptide therapeutics, a proprietary new ...

BAAR, Switzerland - March 18, 2025 (NEWMEDIAWIRE) - PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, published today the invitation to ...

Dr. Peter Wilden, Executive Chairman of PolyPeptide, commented: “Mr. Gonzalez has the right set of skills, experience, and vision to lead our team. Throughout his career, he has been able to leverage ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The hormone glucose-dependent insulinotropic polypeptide (GIP) is considered obesogenic. In contrast, GIP receptor agonists (GIPRAs) have shown reduced feeding and body weight in an obese mouse model.

More information: Liskiewicz et al, Glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via GABAergic neurons in mice. Nature Metabolism (2023). DOI: 10.1038 ...

Baar, 8 August 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the appointment of Stéphane ...